Regorafenib, an oral multikinase inhibitor, has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients that have progressed after all standard therapies. However, novel strategies to improve tolerability and enhance anti-cancer efficacy are needed.
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
DE PALMA, Raffaele;
2017-01-01
Abstract
Regorafenib, an oral multikinase inhibitor, has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients that have progressed after all standard therapies. However, novel strategies to improve tolerability and enhance anti-cancer efficacy are needed.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
pdf definitivo Oncotarget.pdf
accesso aperto
Tipologia:
Documento in versione editoriale
Dimensione
4.59 MB
Formato
Adobe PDF
|
4.59 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
